Pfizer (PFE) Stock Forecast & Price Target

Compare

180 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PFE Analyst Ratings

Moderate Buy

5 Buy

13 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Pfizer

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PFE Stock 12 Month Forecast

Average Price Target

€24.13

▲(11.99%Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Pfizer in the last 3 months. The average price target is €24.13 with a high forecast of €28.06 and a low forecast of €20.41. The average price target represents a 11.99% change from the last price of €21.55.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"€19","24":"€24","29":"€29","21.5":"€21.5","26.5":"€26.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28.06353924,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€28.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.1346437464,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€24.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.40984672,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€20.41</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,21.5,24,26.5,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.505,21.086426095384613,21.66785219076923,22.249278286153846,22.83070438153846,23.412130476923075,23.993556572307693,24.574982667692307,25.156408763076925,25.73783485846154,26.319260953846154,26.90068704923077,27.482113144615386,{"y":28.06353924,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.505,20.78420336510769,21.063406730215384,21.342610095323074,21.62181346043077,21.90101682553846,22.180220190646153,22.459423555753844,22.738626920861538,23.01783028596923,23.297033651076923,23.576237016184614,23.855440381292308,{"y":24.1346437464,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.505,20.497680516923076,20.490361033846153,20.48304155076923,20.475722067692306,20.468402584615383,20.46108310153846,20.45376361846154,20.446444135384617,20.439124652307694,20.43180516923077,20.424485686153847,20.417166203076924,{"y":20.40984672,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.651,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.703,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.942,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.093,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.675,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.774,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.775,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.514,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.182,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.485,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.987,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.505,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 53, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€28.06

Average Price Target€24.13

Lowest Price Target€20.41

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Terence FlynnMorgan Stanley

Morgan Stanley

€27.21

Hold

26.28%

Upside

Reiterated

06/25/25

Morgan Stanley Remains a Hold on Pfizer (PFE)

Courtney BreenBernstein

Bernstein

€25.51

Hold

18.39%

Upside

Reiterated

06/21/25

We rate MRK & PFE Market-Perform.

Vamil DivanGuggenheim

Guggenheim

€28.06

Buy

30.23%

Upside

Reiterated

06/17/25

Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE) and Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT)

Mohit BansalWells Fargo

Wells Fargo

€23.81

Hold

10.49%

Upside

Reiterated

06/17/25

Wells Fargo Sticks to Its Hold Rating for Pfizer (PFE)

Geoff MeachamCiti

Citi

€21.26

Hold

-1.34%

Downside

Reiterated

06/13/25

Citi Keeps Their Hold Rating on Pfizer (PFE)

Trung HuynhUBS

UBS

€21.26

Hold

-1.34%

Downside

Reiterated

06/12/25

Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE) and Chemomab Therapeutics (NASDAQ: CMMB)

Evan SeigermanBMO Capital

BMO Capital

€25.51

Buy

18.39%

Upside

Reiterated

06/12/25

Pfizer's Strategic Positioning in Breast Cancer Market and Growth Potential

Carter GouldCantor Fitzgerald

Cantor Fitzgerald

€20.41

Hold

-5.29%

Downside

Reiterated

06/10/25

Cantor Fitzgerald Remains a Hold on Pfizer (PFE)

Asad HaiderGoldman Sachs

Goldman Sachs

€22.96

Hold

6.55%

Upside

Reiterated

06/09/25

Pfizer's Strategic Opportunities and Market Risks: A Hold Rating Amidst Uncertainties

Tim AndersonBank of America Securities

Bank of America Securities

€22.11→€22.96

Hold

6.55%

Upside

Reiterated

06/06/25

Bank of America Securities Reaffirms Their Hold Rating on Pfizer (PFE)

Akash TewariJefferies

Jefferies

€28.06

Buy

30.23%

Upside

Reiterated

06/04/25

Jefferies Sticks to Their Buy Rating for Pfizer (PFE)

Chris SchottJ.P. Morgan

J.P. Morgan

€25.51

Hold

18.39%

Upside

Reiterated

06/03/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Mersana Therapeutics (NASDAQ: MRSN), Pfizer (NYSE: PFE) and Sanofi (Other OTC: SNYNF)

David RisingerLeerink Partners

Leerink Partners

―

Hold

―

Reiterated

06/02/25

Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE), Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT) and Janux Therapeutics Inc (NASDAQ: JANX)

Nico ChenDBS

DBS

€25.51

Buy

18.39%

Upside

Reiterated

05/30/25

Pfizer's Strong Financial Performance and Promising Pipeline Drive Buy Rating

Kerry HolfordBerenberg Bank

Berenberg Bank

€23.81→€21.26

Hold

-1.34%

Downside

Reiterated

05/29/25

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Pfizer (NYSE: PFE)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Terence FlynnMorgan Stanley

Morgan Stanley

€27.21

Hold

26.28%

Upside

Reiterated

06/25/25

Morgan Stanley Remains a Hold on Pfizer (PFE)

Courtney BreenBernstein

Bernstein

€25.51

Hold

18.39%

Upside

Reiterated

06/21/25

We rate MRK & PFE Market-Perform.

Vamil DivanGuggenheim

Guggenheim

€28.06

Buy

30.23%

Upside

Reiterated

06/17/25

Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE) and Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT)

Mohit BansalWells Fargo

Wells Fargo

€23.81

Hold

10.49%

Upside

Reiterated

06/17/25

Wells Fargo Sticks to Its Hold Rating for Pfizer (PFE)

Geoff MeachamCiti

Citi

€21.26

Hold

-1.34%

Downside

Reiterated

06/13/25

Citi Keeps Their Hold Rating on Pfizer (PFE)

Trung HuynhUBS

UBS

€21.26

Hold

-1.34%

Downside

Reiterated

06/12/25

Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE) and Chemomab Therapeutics (NASDAQ: CMMB)

Evan SeigermanBMO Capital

BMO Capital

€25.51

Buy

18.39%

Upside

Reiterated

06/12/25

Pfizer's Strategic Positioning in Breast Cancer Market and Growth Potential

Carter GouldCantor Fitzgerald

Cantor Fitzgerald

€20.41

Hold

-5.29%

Downside

Reiterated

06/10/25

Cantor Fitzgerald Remains a Hold on Pfizer (PFE)

Asad HaiderGoldman Sachs

Goldman Sachs

€22.96

Hold

6.55%

Upside

Reiterated

06/09/25

Pfizer's Strategic Opportunities and Market Risks: A Hold Rating Amidst Uncertainties

Tim AndersonBank of America Securities

Bank of America Securities

€22.11→€22.96

Hold

6.55%

Upside

Reiterated

06/06/25

Bank of America Securities Reaffirms Their Hold Rating on Pfizer (PFE)

Akash TewariJefferies

Jefferies

€28.06

Buy

30.23%

Upside

Reiterated

06/04/25

Jefferies Sticks to Their Buy Rating for Pfizer (PFE)

Chris SchottJ.P. Morgan

J.P. Morgan

€25.51

Hold

18.39%

Upside

Reiterated

06/03/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Mersana Therapeutics (NASDAQ: MRSN), Pfizer (NYSE: PFE) and Sanofi (Other OTC: SNYNF)

David RisingerLeerink Partners

Leerink Partners

―

Hold

―

Reiterated

06/02/25

Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE), Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT) and Janux Therapeutics Inc (NASDAQ: JANX)

Nico ChenDBS

DBS

€25.51

Buy

18.39%

Upside

Reiterated

05/30/25

Pfizer's Strong Financial Performance and Promising Pipeline Drive Buy Rating

Kerry HolfordBerenberg Bank

Berenberg Bank

€23.81→€21.26

Hold

-1.34%

Downside

Reiterated

05/29/25

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Pfizer (NYSE: PFE)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pfizer

1 Month

xxx

Success Rate

20/36 ratings generated profit

Average Return

+1.02%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +1.02% per trade.

3 Months

xxx

Success Rate

25/36 ratings generated profit

Average Return

+2.86%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 69.44% of your transactions generating a profit, with an average return of +2.86% per trade.

1 Year

Vamil DivanGuggenheim

Success Rate

28/36 ratings generated profit

Average Return

+5.15%

reiterated a buy rating 19 days ago

Copying Vamil Divan's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +5.15% per trade.

2 Years

xxx

Success Rate

28/36 ratings generated profit

Average Return

+7.88%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 77.78% of your transactions generating a profit, with an average return of +7.88% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PFE Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PFE has received 14 Buy Ratings, 53 Hold Ratings, and 0 Sell Ratings. PFE average Analyst price target in the past 3 months is 24.13.

Each month's total comprises the sum of three months' worth of ratings.

PFE Financial Forecast

PFE Earnings Forecast

Next quarter’s earnings estimate for PFE is €0.48 with a range of €0.42 to €0.54. The previous quarter’s EPS was €0.78. PFE beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year PFE has Preformed in-line its overall industry.

PFE Sales Forecast

Next quarter’s sales forecast for PFE is €11.41B with a range of €11.12B to €11.60B. The previous quarter’s sales results were €11.64B. PFE beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year PFE has Preformed in-line its overall industry.

PFE Stock Forecast FAQ

What is DE:PFE’s average 12-month price target, according to analysts?

Based on analyst ratings, Pfizer’s 12-month average price target is 24.13.

What is DE:PFE’s upside potential, based on the analysts’ average price target?

Pfizer has 11.99% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Pfizer a Buy, Sell or Hold?

Pfizer has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 13 hold ratings and 0 sell ratings.

What is Pfizer’s share price target?

The average share price target for Pfizer is 24.13. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €28.06 ,and the lowest forecast is €20.41. The average share price target represents 11.99% Increase from the current price of €21.55.

What do analysts say about Pfizer?

Pfizer’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of Pfizer?

To buy shares of DE:PFE, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Pfizer (PFE) Stock Forecast & Price Target

PFE Analyst Ratings

PFE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Pfizer

PFE Analyst Recommendation Trends

PFE Financial Forecast

PFE Earnings Forecast

PFE Sales Forecast

PFE Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts